MA34559B1 - Formulation pour le traitement du cancer - Google Patents
Formulation pour le traitement du cancerInfo
- Publication number
- MA34559B1 MA34559B1 MA32171A MA32171A MA34559B1 MA 34559 B1 MA34559 B1 MA 34559B1 MA 32171 A MA32171 A MA 32171A MA 32171 A MA32171 A MA 32171A MA 34559 B1 MA34559 B1 MA 34559B1
- Authority
- MA
- Morocco
- Prior art keywords
- cancer
- treatment
- formulation
- kits
- methods
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 238000009472 formulation Methods 0.000 title 1
- KLGQWSOYKYFBTR-UHFFFAOYSA-N 2-nitrobenzamide Chemical class NC(=O)C1=CC=CC=C1[N+]([O-])=O KLGQWSOYKYFBTR-UHFFFAOYSA-N 0.000 abstract 1
- 239000007864 aqueous solution Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Nanotechnology (AREA)
- Molecular Biology (AREA)
- Medical Informatics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Virology (AREA)
- Diabetes (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
LA PRÉSENTE INVENTION CONCERNE DES COMPOSITIONS, DES TROUSSES ET LEURS MÉTHODES D'UTILISATION POUR LE TRAITEMENT DU CANCER ET DE PATHOLOGIES VIRALES. PLUS PARTICULIÈREMENT, L'INVENTION CONCERNE DES COMPOSITIONS PHARMACEUTIQUES CONTENANT DES COMPOSÉS DE NITROBENZAMIDE PRÉSENTANT UNE SOLUBILITÉ ACCRUE DANS DES SOLUTIONS AQUEUSES.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US88075507P | 2007-01-16 | 2007-01-16 | |
PCT/US2008/051214 WO2008089272A1 (fr) | 2007-01-16 | 2008-01-16 | Préparations pour le traitement du cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
MA34559B1 true MA34559B1 (fr) | 2013-10-02 |
Family
ID=39350967
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA32171A MA34559B1 (fr) | 2007-01-16 | 2008-01-16 | Formulation pour le traitement du cancer |
Country Status (33)
Country | Link |
---|---|
US (1) | US20080176946A1 (fr) |
EP (2) | EP2121139B1 (fr) |
JP (1) | JP2010516626A (fr) |
KR (1) | KR20090113852A (fr) |
CN (1) | CN101668561A (fr) |
AU (1) | AU2008206294A1 (fr) |
BR (1) | BRPI0806590A2 (fr) |
CA (1) | CA2674600A1 (fr) |
CO (1) | CO6220840A2 (fr) |
CR (1) | CR10975A (fr) |
CY (1) | CY1113819T1 (fr) |
DK (1) | DK2121139T3 (fr) |
DO (1) | DOP2009000178A (fr) |
EC (1) | ECSP099577A (fr) |
ES (1) | ES2395690T3 (fr) |
GB (1) | GB2447796C (fr) |
GT (1) | GT200900201A (fr) |
HK (2) | HK1121697A1 (fr) |
HR (1) | HRP20120960T1 (fr) |
IL (1) | IL199682A0 (fr) |
MA (1) | MA34559B1 (fr) |
MX (1) | MX2009007596A (fr) |
NZ (1) | NZ579098A (fr) |
PL (1) | PL2121139T3 (fr) |
PT (1) | PT2121139E (fr) |
RS (1) | RS52633B (fr) |
RU (2) | RU2481830C2 (fr) |
SG (1) | SG178714A1 (fr) |
SI (1) | SI2121139T1 (fr) |
SV (1) | SV2009003335A (fr) |
TN (1) | TN2009000292A1 (fr) |
UA (1) | UA100852C2 (fr) |
WO (1) | WO2008089272A1 (fr) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7961081B2 (en) * | 2003-05-22 | 2011-06-14 | John Tomlienovic | Anti-theft system and method |
KR20080031266A (ko) * | 2005-06-10 | 2008-04-08 | 바이파 사이언스 인코포레이티드 | Parp 조절제 및 암의 치료 |
CN101242822B (zh) | 2005-07-18 | 2011-08-24 | 彼帕科学公司 | 治疗卵巢癌的药物 |
US20080262062A1 (en) * | 2006-11-20 | 2008-10-23 | Bipar Sciences, Inc. | Method of treating diseases with parp inhibitors |
CA2655257A1 (fr) * | 2006-06-12 | 2008-12-04 | Bipar Sciences, Inc. | Procede permettant de traiter des maladies avec des inhibiteurs de parp |
US20100160442A1 (en) * | 2006-07-18 | 2010-06-24 | Ossovskaya Valeria S | Formulations for cancer treatment |
JP2010502730A (ja) | 2006-09-05 | 2010-01-28 | バイパー サイエンシズ,インコーポレイティド | 癌の治療法 |
CN101534836B (zh) | 2006-09-05 | 2011-09-28 | 彼帕科学公司 | Parp抑制剂在制备治疗肥胖症的药物中的用途 |
US7538252B2 (en) * | 2006-09-05 | 2009-05-26 | Bipar Sciences, Inc. | Drug design for tubulin inhibitors, compositions, and methods of treatment thereof |
WO2009051815A1 (fr) * | 2007-10-19 | 2009-04-23 | Bipar Sciences, Inc. | Procédés et compositions pour le traitement du cancer au moyen d'inhibiteurs de parp de type benzopyrone |
WO2009064738A2 (fr) | 2007-11-12 | 2009-05-22 | Bipar Sciences, Inc. | Traitement de cancer du sein avec un inhibiteur parp seul ou en combinaison avec des agents anti-tumoraux |
US20090275608A1 (en) * | 2008-02-04 | 2009-11-05 | Bipar Sciences, Inc. | Methods of diagnosing and treating parp-mediated diseases |
US8026271B2 (en) * | 2008-07-11 | 2011-09-27 | National Health Research Institutes | Formulations of indol-3-yl-2-oxoacetamide compounds |
WO2010036226A1 (fr) * | 2008-09-26 | 2010-04-01 | George Nelson | Méthode de traitement de la polyarthrite rhumatoïde, des tremblements/de la maladie de parkinson et de la sclérose en plaques |
MX2011003277A (es) * | 2008-10-14 | 2012-09-21 | Salubrious Pharmaceuticals LLC | Proceso para el tratamiento de la artritis reumatoide, temblores/enfermedad de parkinson, esclerosis multiple y cancer de tipo no viral. |
EP2709618A4 (fr) * | 2011-05-10 | 2014-11-05 | UNIVERSITé LAVAL | Procédés pour le traitement et le diagnostic de l'hypertension artérielle pulmonaire |
IL266415B2 (en) * | 2012-11-30 | 2024-03-01 | Glaxosmithkline Llc | Innovative pharmaceutical composition |
WO2017192618A1 (fr) | 2016-05-02 | 2017-11-09 | Symbios Technologies, Inc. | Agents chimiothérapeutiques aqueux activés par plasma électrochimique |
EP3655418A4 (fr) | 2017-06-22 | 2021-05-19 | Triact Therapeutics, Inc. | Procédés de traitement d'un glioblastome |
MX2020003760A (es) | 2017-09-26 | 2020-07-29 | Tesaro Inc | Formulaciones de niraparib. |
EP3687501A4 (fr) * | 2017-09-29 | 2021-06-23 | Triact Therapeutics, Inc. | Formulations d'iniparib et leurs utilisations |
WO2020246737A1 (fr) * | 2019-06-04 | 2020-12-10 | 사회복지법인 삼성생명공익재단 | Composition pour le traitement du cancer de la prostate résistant à la castration, comprenant des quassinoïdes |
CZ309587B6 (cs) * | 2021-01-22 | 2023-05-03 | Oncora S.R.O. | Mikroemulzní prekoncentrát s obsahem kladribinu a způsob jeho přípravy |
GB2611315B (en) * | 2021-09-29 | 2024-01-03 | Siemens Healthcare Gmbh | Method of operating a magnetic resonance scanner |
WO2023239919A1 (fr) * | 2022-06-10 | 2023-12-14 | Dana-Farber Cancer Institute, Inc. | Un déséquilibre allélique de l'accessibilité de la chromatine dans le cancer identifie des variants de risque causal et leurs mécanismes |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0348655A (ja) * | 1989-07-14 | 1991-03-01 | Shionogi & Co Ltd | プロスタグランジンd↓2類の安定化 |
US5633282A (en) * | 1990-05-25 | 1997-05-27 | British Technology Group Limited | Inhibition of viral infection |
US5637618A (en) * | 1990-06-01 | 1997-06-10 | Bioresearch, Inc. | Specific eatable taste modifiers |
US5631038A (en) * | 1990-06-01 | 1997-05-20 | Bioresearch, Inc. | Specific eatable taste modifiers |
US5232735A (en) * | 1990-06-01 | 1993-08-03 | Bioresearch, Inc. | Ingestibles containing substantially tasteless sweetness inhibitors as bitter taste reducers or substantially tasteless bitter inhibitors as sweet taste reducers |
US5484951A (en) * | 1990-10-19 | 1996-01-16 | Octamer, Incorporated | 5-iodo-6-amino-6-nitroso-1,2-benzopyrones useful as cytostatic and antiviral agents |
US5482975A (en) * | 1991-10-22 | 1996-01-09 | Octamer, Inc. | Adenosine diphosphoribose polymerase binding nitroso aromatic compounds useful as retroviral inactivating agents, anti-retroviral agents and anti-tumor agents |
US5877185A (en) * | 1991-10-22 | 1999-03-02 | Octamer, Inc. | Synergistic compositions useful as anti-tumor agents |
US5753674A (en) * | 1991-10-22 | 1998-05-19 | Octamer, Inc. | Adenosine diphosphoribose polymerase binding nitroso aromatic compounds useful as retroviral inactivating agents, anti-retroviral agents, anti-retroviral agents and anti-tumor agents |
US5516941A (en) * | 1991-10-22 | 1996-05-14 | Octamer, Inc. | Specific inactivators of "retroviral" (asymmetric) zinc fingers |
US5464871A (en) | 1993-05-12 | 1995-11-07 | Octamer, Inc. | Aromatic nitro and nitroso compounds and their metabolites useful as anti-viral and anti-tumor agents |
GB9200247D0 (en) * | 1992-01-07 | 1992-02-26 | Erba Carlo Spa | Pharmaceutical compositions containing polymer derivative-bound anthracycline glycosides and a method for their preparation |
US5558855A (en) | 1993-01-25 | 1996-09-24 | Sonus Pharmaceuticals | Phase shift colloids as ultrasound contrast agents |
US6015792A (en) * | 1993-05-26 | 2000-01-18 | Bioresearch, Inc. | Specific eatable taste modifiers |
US6008250A (en) * | 1993-05-26 | 1999-12-28 | Bioresearch, Inc. | Specific eatable taste modifiers |
US5589483A (en) * | 1994-12-21 | 1996-12-31 | Geron Corporation | Isoquinoline poly (ADP-ribose) polymerase inhibitors to treat skin diseases associated with cellular senescence |
WO1996038175A1 (fr) * | 1995-06-02 | 1996-12-05 | Takeda Chemical Industries, Ltd. | Composition stabilisee comprenant un benzimidazole anti-ulcereux |
US5837729A (en) * | 1996-04-26 | 1998-11-17 | Metatron, Inc. | Methods for treating and preventing HIV infection using acetaminophen and derivatives thereof |
US6225323B1 (en) * | 1997-04-10 | 2001-05-01 | Joseph Koziak | Activated iododerivatives for the treatment of cancer and AIDS |
US5908861A (en) * | 1997-05-13 | 1999-06-01 | Octamer, Inc. | Methods for treating inflammation and inflammatory disease using pADPRT inhibitors |
US6696426B2 (en) * | 2000-08-22 | 2004-02-24 | Pharmacia Corporation | Preservative free ophthalmic oxazolidinone antibiotic drug delivery systems |
JPWO2002055076A1 (ja) * | 2001-01-04 | 2004-05-13 | 第一製薬株式会社 | シクロデキストリン製剤 |
US20050113283A1 (en) * | 2002-01-18 | 2005-05-26 | David Solow-Cordero | Methods of treating conditions associated with an EDG-4 receptor |
JP2003321364A (ja) * | 2002-05-07 | 2003-11-11 | Eisai Co Ltd | シクロデキストリンにより可溶化及び安定化された抗腫瘍剤含有組成物 |
CA2513331A1 (fr) * | 2003-01-14 | 2004-08-05 | Teva Pharmaceutical Industries Ltd | Formulations parenterales contenant un peptide utilisees dans le traitement du lupus erythemateux systemique |
WO2005023765A1 (fr) * | 2003-09-11 | 2005-03-17 | Pharmacia & Upjohn Company Llc | Methode de catalyse de reactions d'amidation au moyen de co2 |
KR20080031266A (ko) * | 2005-06-10 | 2008-04-08 | 바이파 사이언스 인코포레이티드 | Parp 조절제 및 암의 치료 |
CN101242822B (zh) * | 2005-07-18 | 2011-08-24 | 彼帕科学公司 | 治疗卵巢癌的药物 |
CA2655257A1 (fr) * | 2006-06-12 | 2008-12-04 | Bipar Sciences, Inc. | Procede permettant de traiter des maladies avec des inhibiteurs de parp |
JP2010502730A (ja) * | 2006-09-05 | 2010-01-28 | バイパー サイエンシズ,インコーポレイティド | 癌の治療法 |
EP2059802A4 (fr) * | 2006-09-05 | 2010-09-08 | Bipar Sciences Inc | Procedes de conception d'inhibiteurs de parp et leurs utilisations |
US7538252B2 (en) * | 2006-09-05 | 2009-05-26 | Bipar Sciences, Inc. | Drug design for tubulin inhibitors, compositions, and methods of treatment thereof |
CN101534836B (zh) * | 2006-09-05 | 2011-09-28 | 彼帕科学公司 | Parp抑制剂在制备治疗肥胖症的药物中的用途 |
-
2008
- 2008-01-16 PL PL08727771T patent/PL2121139T3/pl unknown
- 2008-01-16 JP JP2009545734A patent/JP2010516626A/ja not_active Withdrawn
- 2008-01-16 CN CN200880008617A patent/CN101668561A/zh active Pending
- 2008-01-16 GB GB0807263A patent/GB2447796C/en not_active Withdrawn - After Issue
- 2008-01-16 KR KR1020097017060A patent/KR20090113852A/ko not_active Application Discontinuation
- 2008-01-16 NZ NZ579098A patent/NZ579098A/en not_active IP Right Cessation
- 2008-01-16 AU AU2008206294A patent/AU2008206294A1/en not_active Withdrawn
- 2008-01-16 CA CA002674600A patent/CA2674600A1/fr not_active Withdrawn
- 2008-01-16 UA UAA200908564A patent/UA100852C2/ru unknown
- 2008-01-16 MA MA32171A patent/MA34559B1/fr unknown
- 2008-01-16 SG SG2012003109A patent/SG178714A1/en unknown
- 2008-01-16 RS RS20120544A patent/RS52633B/en unknown
- 2008-01-16 WO PCT/US2008/051214 patent/WO2008089272A1/fr active Application Filing
- 2008-01-16 MX MX2009007596A patent/MX2009007596A/es active IP Right Grant
- 2008-01-16 BR BRPI0806590-0A patent/BRPI0806590A2/pt not_active Application Discontinuation
- 2008-01-16 SI SI200830855T patent/SI2121139T1/sl unknown
- 2008-01-16 RU RU2009130599/15A patent/RU2481830C2/ru not_active IP Right Cessation
- 2008-01-16 PT PT87277711T patent/PT2121139E/pt unknown
- 2008-01-16 ES ES08727771T patent/ES2395690T3/es active Active
- 2008-01-16 US US12/015,403 patent/US20080176946A1/en not_active Abandoned
- 2008-01-16 DK DK08727771.1T patent/DK2121139T3/da active
- 2008-01-16 EP EP08727771A patent/EP2121139B1/fr active Active
- 2008-01-16 EP EP11192725A patent/EP2476461A3/fr not_active Withdrawn
-
2009
- 2009-02-26 HK HK09101870.4A patent/HK1121697A1/xx not_active IP Right Cessation
- 2009-07-02 IL IL199682A patent/IL199682A0/en unknown
- 2009-07-07 TN TNP2009000292A patent/TN2009000292A1/fr unknown
- 2009-07-14 DO DO2009000178A patent/DOP2009000178A/es unknown
- 2009-07-15 SV SV2009003335A patent/SV2009003335A/es unknown
- 2009-07-15 GT GT200900201A patent/GT200900201A/es unknown
- 2009-08-13 EC EC2009009577A patent/ECSP099577A/es unknown
- 2009-08-14 CO CO09085583A patent/CO6220840A2/es not_active Application Discontinuation
- 2009-08-14 CR CR10975A patent/CR10975A/es unknown
-
2010
- 2010-05-24 HK HK10105011.2A patent/HK1137158A1/xx not_active IP Right Cessation
-
2012
- 2012-11-23 HR HRP20120960AT patent/HRP20120960T1/hr unknown
- 2012-12-03 RU RU2012151571/15A patent/RU2012151571A/ru unknown
-
2013
- 2013-01-09 CY CY20131100023T patent/CY1113819T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA34559B1 (fr) | Formulation pour le traitement du cancer | |
MA44674A (fr) | Inhibiteurs de bromodomaine | |
MA38175B1 (fr) | Lactames fusionnés à un aryle et hétéroaryle | |
MA32876B1 (fr) | Anticorps dirigés contre l'angiopoïétine 2 humaine | |
MA30333B1 (fr) | Aminotetrahydropyranes utiles en tant qu'inhibiteurs de la dipeptidyle peptidase-iv pour le traitement ou la prevention du diabete. | |
MA44851B1 (fr) | Dérivés pyridinyltriazole substitués par des groupements amides et leurs utilisations | |
TN2010000154A1 (fr) | Composition destinee a la regulation du metabolism des lipides | |
EA201000599A1 (ru) | Ингибиторы тирозинкиназы брутона | |
MA34732B1 (fr) | Spiro-oxindoles antagonistes de mdm2 | |
MA33815B1 (fr) | Antagonistes, de type spiro-oxindole, de l'oncoprotéine mdm2 | |
MA31183B1 (fr) | Inhibiteurs de mek | |
ATE447574T1 (de) | 3-amino-4-phenylbutansäurederivate als dipeptidylpeptidase-hemmer zur behandlung oder vorbeugung von diabetes | |
MX2009007337A (es) | Indazoles sustituidos con 5-piridinona. | |
MA32134B1 (fr) | Composés hétérocycliques | |
MA32887B1 (fr) | Aminotetrahydropyranes en tant qu'inhibiteurs de dipeptidyle peptidase-iv pour le traitement ou la prevention du diabete | |
EA200901166A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr 119 | |
MA34926B1 (fr) | Composition effervescente sous forme solide utilisable dans des applications vaginales pour le traitement d'infections vaginales | |
DK1206474T3 (da) | Sulfonylphenylpyrazolforbindelser anvendelige som cox-2-inhibitorer | |
ATE540950T1 (de) | Aminocyclohexane als dipeptidylpeptidase-iv- hemmer zur behandlung bzw. prävention von diabetes | |
EA201000897A1 (ru) | Соединения и фармацевтические композиции для снижения уровня мочевой кислоты | |
EA200800726A1 (ru) | Введение ингибиторов дипептидилпептидазы | |
EP1841426A4 (fr) | Carbinamines tertiaires incluant des heterocycles substitues, agissant en tant qu'inhibiteurs de la beta-secretase et utilisees dans le traitement de la maladie d'alzheimer | |
EA200970916A1 (ru) | Соединения 5,6-дигидро-1н-пиридин-2-она | |
NO20084821L (no) | Formuleringer og metoder for celleimaging og terapi | |
MA50406B1 (fr) | Inhibiteurs pyrazole de magl |